KORDON KANI VE WHARTON JELİ KAYNAKLI MEZENKİMAL KÖK HÜCRELERİN İMMUNOMODÜLATÖR ÖZELLİKLERİNİN KARŞILAŞTIRILMASI
Amaç: Mezenkimal kök hücreler (MKH’ler), immün düzenleyici özellikleri nedeniyle bir çok immün sistem ilişkili hastalık için tedavi seçeneği olarak umut vaad etmektedir. Wharton Jeli (WJ-MKH) ve kordon kanı (KK-MKH), diğer MKH kaynaklarına göre son dönemlerde daha çok ilgi görmektedir. Çalışmada, WJ-MKH’ler ve KK-MKH’lerin immünolojik etkilerinin mekanizmalarındaki farkı araştırmak amaçlanmıştır. Gereç ve Yöntem: Periferik kan mononükler hücreler (PKMH) ve MKH ko-kültür öncesi ve sonrası CD4+ T hücrelerin hücre içi sitokin seviyeleri (Interlökin-4 (IL-4), Interferon-γ (IFN-γ), and Interlökin-17 (IL-17)) flow sitometri ile tespit edildi. Aynı zamanda Tümör büyüme faktörü (TGF)-β, IL-4, IL-17, IFN-γ süpernatant sitokin seviyeleri ELISA ile ölçüldü. Çalışmada, ko-kültür MKH/PKMH 1/5 ve 1/10 oranlarında, 24 saat ve 72 saat inkübasyon süreleri uygulandı. Bulgular: Verilerimiz WJ-MKH’lerin ve KK-MKH’lerin farklı morfolojik özellikleri, çoğalma kapasiteleri, çoğalma süreleri ve immünomodülasyon yetenekleri olduğunu gösterdi. IFN-γ, KK-MKH/PKMH ko-kültür sonrası WJ-MKH/PKMH ko-kültürü sonrasına göre hücre içerisinde hem 1/5 hem 1/10 oranlarında 24. saatlerde anlamlı derecede azalırken, 72. saatlerde anlamlı derecede arttı (p<0,05). IL-17 sitokinin için farklı olarak sadece 72. saatte KK-MKH grubunda WJ-MKH grubuna göre anlamlı derecede hücre içi seviyesi düştü. IL-4 için KK-MKH grubunda 1/10 oran 24 saatte hücre içi seviyesi anlamlı derecede düşerken diğer tüm gruplarda artış gösterdi. KK-MKH/PKMH ko-kültür sonrası TGF-β supernatant seviyesi 1/5 oranında 24 saatte azalırken 72 saatte artış gösterdi. 1/10 oranlarında ise tam tersi 24. saatte KK-MKH grubunda artarken 72 saatlerde anlamlı derecede azaldı (p<0,05). Sonuç: KK-MKH‘ler ve WJ-MKH’ler, farklı immünmodülatör özellikler göstermektedir. Bu bulgular, KK-MKH’lerin izolasyonun, çoğalma kapasitesinin ve immünmodülatör özelliklerinin farklı olması sebebiyle hücre tedavileri açısından WJ-MKH’lerin kullanılmasının daha avantajlı olduğu söylenebilir.
COMPARISON OF THE IMMUNOMODULATORY PROPERTIES OF THE CORD BLOOD AND WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELLS
Objective: Mesenchymal stem cells (MSCs) are promising as a treatment option for many immune-related diseases due to their immune regulatory properties. Wharton’s Jelly (WJ-MSC) and cord blood (CB-MSC) have recently received more attention than the other MSC sources. In this study, it was aimed to investigate the difference in the mechanisms of the immunological effects of WJ-MSCs and CB-MSCs. Material and Methods: The intracellular cytokine levels of peripheral blood mononuclear cells (PBMC) and CD4+ T cells before and after MSC co-culture (Interleukin-4 (IL-4), Interferon-γ (IFN-γ), and Interleukin-17 (IL17)) were determined by flow cytometry. At the same time, tumor growth factor (TGF)-β, IL-4, IL-17, IFN-γ supernatant cytokine levels were measured by ELISA. In the study, incubation times of 24 hours and 72 hours were applied with co-culture MSC/PBMC ratios of 1/5 and 1/10. Results: Our data showed that WJ-MSCs and CB-MSCs have different morphological features, proliferation capacities, proliferation times and immunomodulating abilities. One of the cytokines of IFN-γ decreased significantly at both 1/5 and 1/10 ratios in the cell at 24 hours and increased significantly at 72 hours after CB-MSC/PBMC co-culture compared to the level after WJ-MSC/PBMC co-culture (p<0.05). Unlike for IL-17 cytokine, the intracellular level decreased significantly in the CB-MSC group only at 72 hours compared to the WJ-MSC group. For IL-4, the 1/10 ratio in the CB-MSC group decreased significantly at 24 hours, while the intracellular level was increased in all other groups. After CB-MSC/PBMC co-culture, TGF-β supernatant level decreased by 1/5 in 24 hours and increased in 72 hours. On the contrary, TGF-β supernatant level increased in the CB-MSC group at 24 hours and decreased significantly at 72 hours in 1/10 ratios (p<0.05). Conclusion: CB-MSCs and WJ-MSCs show different immunomodulatory properties. Based on these findings, it can be said that the use of WJ-MSCs is more advantageous in terms of cell therapies due to the different isolation, proliferation capacity and immunomodulatory properties of CB-MSCs.
___
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8(4):315-7. google scholar
- Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363(9419):1439-41. google scholar
- Atala A. Recent developments in tissue engineering and regenerative medicine. Curr Opin Pediatr 2006;18(2):167-71. google scholar
- Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003;33(6):919-26. google scholar
- Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006;24(5):1294-301. google scholar
- Zheng YB, Gao ZL, Xie C, Zhu HP, Peng L, Chen JH, et al. Characterization and hepatogenic differentiation of mesenchymal stem cells from human amniotic fluid and human bone marrow: a comparative study. Cell Biol Int 2008;32(11):1439-48. google scholar
- Chen L, Tredget EE, Liu C, Wu Y. Analysis of allogenicity of mesenchymal stem cells in engraftment and wound healing in mice. PLoS One 2009;4:e7119. doi: 10.1371/journal.pone.0007119 google scholar
- De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A, Pascual CY, Aller MA, Arias J, et al. Immuno-suppressive properties of mesenchymal stem cells: Advances and applications. Curr Mol Med 2012;12(5):574-91. google scholar
- Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev Immunol 2008;8(9):726-36. google scholar
- Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006;24(2):386-98. google scholar
- Kogler G, Radke TF, Lefort A, Sensken S, Fischer J, Sorg RV, et al. Cytokine production and hematopoiesis supporting activity of cord blood-derived unrestricted somatic stem cells. Exp Hematol 2005;33(5):573-83. google scholar
- Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008;26(1):212-22. google scholar
- Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99(10):3838-43. google scholar
- Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003;101(9):3722-9. google scholar
- Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 2008;36(3):309-18. google scholar
- Bieback K, Kern S, Klüter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004;22(4):625-34. google scholar
- Zeddou M, Briquet A, Relic B, Josse C, Malaise MG, Gothot A, et al. The umbilical cord matrix is a better source of mesenchymal stem cells (MSC) than the umbilical cord blood. Cell Biol Int 2010;34(7):693-701. google scholar
- Galipeau J, Sensebe L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell 2018;22(6):824-33. google scholar
- Weiss ARR, Dahlke MH. Immunomodulation by mesenchymal stem cells (MSCs): Mechanisms of action of living, apoptotic, and dead mscs. Front Immunol 2019;10:1191. google scholar
- Kim JH, Jo CH, Kim HR, Hwang YI. Comparison of immunological characteristics of mesenchymal stem cells from the periodontal ligament, umbilical cord, and adipose tissue. Stem Cells Int 2018;8429042. google scholar
- Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK, et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006;81(11):1589-95. google scholar
- Sudres M, Norol F, Trenado A, Gregoire S, Charlotte F, Levacher B, et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006;176(12):7761-7. google scholar